BRAF and lentigo maligna melanoma: In the CLND group, ulceration (HR 4.9, 95% CI 2.14–11.18, p < 0.001) and nodular melanoma (HR 4.25, 95% CI 1.27–14.21, p = 0.019) were strongly associated with the risk of relapse, whilst stage IIIC (HR 1.91, 95% CI 1.01–3.63, p = 0.047), lentigo maligna melanoma histology (HR 0.51, 95% CI 0.26–0.99, p = 0.048), and BRAF mutation (HR 0.35, 95% CI 0.13–0.92, p = 0.034) showed a weaker association.